 Current News April 18, 2011
Med BioGene Announces Closing of Partnership with Precision Therapeutics to Commercialize LungExpress Dx
April 13, 2011
Med BioGene Shareholders Approve Commercialization Partnership with Precision Therapeutics
March 28, 2011
Med BioGene Accepts Improved Offer from Precision Therapeutics to Commercialize LungExpress Dx; Rejects Offer from Signal Genetics
March 23, 2011
Med BioGene Receives Offer from Signal Genetics and Respira Health to Commercialize LungExpress Dx
March 01, 2011
Precision Therapeutics and Med BioGene Partner to Commercialize LungExpress Dx
News Archives 2011
|
Med BioGene Announces New Address and Contact Particulars
April 29, 2011
VANCOUVER, BC — Med BioGene Inc. (TSXV: MBI) today announced the following new address and contact particulars: Med BioGene Inc. About Med BioGene MBI is a life science company focused on the development and commercialization of genomic-based personalized clinical laboratory diagnostic tests. MBI is committed to advancing personalized medicine by commercializing tests that provide clinically relevant information to improve patient treatment and reduce health care costs. MBI and Precision Therapeutics have partnered to commercialize MBI’s flagship test, LungExpress Dx. For more information on MBI, please visit www.medbiogene.com. For more information on Precision Therapeutics, please visit www.precisiontherapeutics.com. For corporate information, please contact: Erinn B. Broshko The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
| 
|
Home 
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer